Exploring the Impact of Beta-Blockers Post-Acute Myocardial Infarction in Patients with Preserved Ejection Fraction: A Meta-Analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Beta-blocker therapy after myocardial infarction: an umbrella review.EClinicalMedicine · 2026
   Article
2. Beta-blocker therapy after myocardial infarction with preserved LVEF (≥50%): a systematic review and Bayesian meta-analysis with time-to-event reconstruction.American heart journal plus : cardiology research and practice · 2026
   Review
3. Impact of β-blocker therapy after acute myocardial infarction in patients with preserved ejection fraction: a meta-analysis.Archives of medical sciences. Atherosclerotic diseases · 2026
   Review
4. Sodium-glucose cotransporter 2 inhibitors reduce new-onset heart failure and death after myocardial infarction with a preserved ejection fraction following coronary intervention.American journal of translational research · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as